0HIY Stock Overview Engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Atara Biotherapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Atara Biotherapeutics Historical stock prices Current Share Price US$11.03 52 Week High US$39.40 52 Week Low US$6.56 Beta 0.54 1 Month Change -0.65% 3 Month Change 47.44% 1 Year Change -18.01% 3 Year Change -97.42% 5 Year Change n/a Change since IPO -98.82%
Recent News & Updates
New minor risk - Profitability Nov 20
Third quarter 2024 earnings released: US$2.94 loss per share (vs US$16.40 loss in 3Q 2023) Nov 14
New major risk - Revenue and earnings growth Nov 14
Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer Oct 18 Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million. Sep 04
See more updates
New minor risk - Profitability Nov 20
Third quarter 2024 earnings released: US$2.94 loss per share (vs US$16.40 loss in 3Q 2023) Nov 14
New major risk - Revenue and earnings growth Nov 14
Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer Oct 18 Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million. Sep 04
Insufficient new directors Sep 01
Second quarter 2024 earnings released: US$3.10 loss per share (vs US$16.92 loss in 2Q 2023) Aug 13 Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024
Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease Jul 17
New major risk - Financial position Jul 01
New minor risk - Insider selling May 22
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA May 22
First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.72 loss in 1Q 2023) May 10
Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024 Apr 28
Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022) Mar 29
Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis Feb 14
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology Feb 01 Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.
Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024 Jan 08
Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting Dec 12
Independent Director recently bought US$101k worth of stock Nov 16
New minor risk - Market cap size Nov 10
Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis Nov 09 Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.
New major risk - Financial position Nov 03 Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Nov 02
Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022) Nov 02
New major risk - Negative shareholders equity Nov 02
Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability Sep 20
New major risk - Revenue and earnings growth Aug 10
Second quarter 2023 earnings released: US$0.68 loss per share (vs US$0.18 profit in 2Q 2022) Aug 09
Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
New major risk - Financial position Jul 03
Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors Jun 06
Insufficient new directors Jun 01
President recently sold US$61k worth of stock May 22
Atara Biotherapeutics, Inc. Announces Executive Changes May 09
Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021) Feb 09
Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM) Feb 09
Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023 Feb 07
Atara Biotherapeutics Announces Changes to Its Board of Directors Dec 21 Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting Dec 13
Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022 Oct 26
CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Oct 15 Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022
Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Aug 02
Now 35% undervalued Jul 13
Atara Biotherapeutics, Inc. Announces Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS Jul 13
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress Jun 05
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer May 20
Atara and MSK Expects to Provide A Phase 1 Data Update for Ata2271 in Second Half 2022 May 06 Atara Biotherapeutics, Inc. Names Charlene Banard as Chief Technical Officer
Atara Biotherapeutics, Inc. Provides Update on ATA2271 Autologous CAR T Trial Feb 19
Atara Biotherapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 28, 2022 Feb 18
FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million. Jan 27
Atara Biotherapeutics, Inc. Lauds the Second High Impact Study This Month Solidifying EBV as the Primary Driver of the Development of MS Jan 25
Atara Biotherapeutics, Inc. to Complete the Biologics License Application for Patients with EBV+ PTLD in Second Quarter of 2022 Jan 12
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting Dec 15
Atara Biotherapeutics, Inc. Announces New Preclinical and Preliminary Clinical Results for ATA2271 at ESMO Immuno-Oncology Congress 2021 Dec 10
Atara Biotherapeutics, Inc. Announces That the Marketing Authorization Application for Tabelecleucel (Tab-Cel®) Has Been Fully Validated by the European Medicines Agency Dec 01
High number of new directors Oct 31
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of Tab-Cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ptld) Sep 29
High number of new directors Sep 02
Atara Biotherapeutics Announces Operational Progress on Tabelecleucel (Tab-Cel®) for Post-Transplant Lymphoproliferative Disease (PTLD) Aug 12
SVP & Chief Commercial Officer recently bought US$500k worth of stock Jun 17
Atara Biotherapeutics Presents Positive Tab-Cel Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect Jun 08
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from A Combined Analysis of Phase 2 Tab-Cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease At the Ebmt 2021 Annual Meeting Mar 15
Atara Biotherapeutics, Inc. Reports Operational Progress Mar 04
Atara Biotherapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Feb 19
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Feb 09
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel(R) for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease Jan 05
Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $174.999792 million. Dec 11
Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219 at the 62 American Society of Hematology Annual Meeting Dec 10
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors Dec 09 Shareholder Returns 0HIY GB Biotechs GB Market 7D 5.4% -5.1% -2.2% 1Y -18.0% -24.5% 2.4%
See full shareholder returns
Return vs Industry: 0HIY exceeded the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0HIY underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0HIY's price volatile compared to industry and market? 0HIY volatility 0HIY Average Weekly Movement 13.9% Biotechs Industry Average Movement 7.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0HIY's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HIY's weekly volatility has decreased from 19% to 14% over the past year, but is still higher than 75% of UK stocks.
About the Company Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
Show more Atara Biotherapeutics, Inc. Fundamentals Summary How do Atara Biotherapeutics's earnings and revenue compare to its market cap? 0HIY fundamental statistics Market cap US$65.66m Earnings (TTM ) -US$133.16m Revenue (TTM ) US$100.44m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0HIY income statement (TTM ) Revenue US$100.44m Cost of Revenue US$180.37m Gross Profit -US$79.93m Other Expenses US$53.23m Earnings -US$133.16m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -23.12 Gross Margin -79.58% Net Profit Margin -132.58% Debt/Equity Ratio 0%
How did 0HIY perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 07:20 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Atara Biotherapeutics, Inc. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution John Newman Canaccord Genuity Yigal Nochomovitz Citigroup Inc Jonathan Miller Evercore ISI
Show 12 more analysts 